(18.02.2020)

Israel based Vaxil Bio Ltd. announced an update to the Company’s press release dated February 13, 2020, regarding the possible identification of a novel coronavirus vaccine candidate, Vaccine Candidate.

Vaxil said in a newly published press release on February 18, 2020, the Vaccine Candidate is based on unique and patent-protected signal peptide technology, utilizing Vaxil’s proprietary VaxHit™ bioinformatics platform.